← Back to Search

Radiation Therapy

External Beam Radiation Therapy for Prostate Cancer

Phase 2
Waitlist Available
Led By Cynthia Menard, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Delivery of conformal radiation therapy following radical prostatectomy is limited by the inability to define the clinical target volume (CTV). This stems from a poor understanding of patterns of local recurrence and limitations of standard imaging techniques.Magnetic Resonance Imaging (MRI) is a promising modality for imaging the prostatic bed following radical prostatectomy. MRI provides more detailed postoperative anatomy to guide CTV delineation, the ability to document local recurrence patterns, and a method to assess intrafraction prostatic bed motion and deformity to define appropriate planning target volume margins. The aim of this pilot study is to develop a technique for external beam radiation therapy (EBRT) following radical prostatectomy based on MRI-delineation of the CTV. Twenty patients will be enrolled in this pilot, development phase.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2018 Phase 1 trial • 51 Patients • NCT02783599
53%
Nausea
47%
Fatigue
43%
Stomatitis
39%
Constipation
33%
Decreased appetite
31%
Alopecia
25%
Asthenia
24%
Vomiting
24%
Diarrhoea
22%
Anaemia
22%
Neutrophil count decreased
20%
Neutropenia
18%
Febrile neutropenia
18%
Pyrexia
18%
White blood cell count decreased
18%
Dizziness
16%
Myalgia
16%
Headache
14%
Abdominal pain
14%
Oropharyngeal pain
14%
Oedema peripheral
12%
Dyspepsia
12%
Insomnia
12%
Arthralgia
12%
Dysgeusia
10%
Abdominal pain upper
8%
Flatulence
8%
Procedural pain
8%
Chills
8%
Platelet count decreased
8%
Pain in extremity
8%
Tumour pain
6%
Anxiety
6%
Abdominal distension
6%
Hypoalbuminaemia
6%
Urinary tract infection
6%
Infusion related reaction
6%
Blood creatinine increased
6%
Hypokalaemia
6%
Catarrh
6%
Rash
6%
Cough
6%
Dyspnoea
4%
Sepsis
2%
Deep vein thrombosis
2%
Atrial fibrillation
2%
Gastrointestinal obstruction
2%
Anaphylactic reaction
2%
Device related infection
2%
Cardiopulmonary failure
2%
Bronchitis
2%
Influenza
2%
Guillain-barre syndrome
2%
Intestinal perforation
2%
Anal abscess
2%
Joint effusion
2%
Encephalopathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Olaratumab + Doxorubicin

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: External Beam Radiation TherapyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
External Beam Radiotherapy
1995
Completed Phase 3
~440

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,525 Previous Clinical Trials
503,178 Total Patients Enrolled
66 Trials studying Prostate Cancer
15,592 Patients Enrolled for Prostate Cancer
Princess Margaret Hospital, CanadaOTHER
119 Previous Clinical Trials
39,041 Total Patients Enrolled
9 Trials studying Prostate Cancer
9,540 Patients Enrolled for Prostate Cancer
Cynthia Menard, MDPrincipal InvestigatorPrincess Margaret Hospital, Canada
1 Previous Clinical Trials
45 Total Patients Enrolled
~1 spots leftby Nov 2025